User:Mr. Ibrahem/Piperaquine/dihydroartemisinin

Piperaquine/dihydroartemisinin (DHA/PPQ), sold under the brand name Eurartesim among others, is a fixed dose combination medication used in the treatment of malaria. It is a combination of piperaquine and dihydroartemisinin. Specifically it is used for malaria of the P. falciparum and P. vivax types. It is taken by mouth.

Side effects are uncommon. Concerns include the possibility of QT prolongation. Versions are available for use in children. Use in early pregnancy is not recommended. The two medications work by different mechanisms.

Piperaquine/dihydroartemisinin was approved for medical use in Europe in 2011. It is on the World Health Organization's List of Essential Medicines. While it was available for about US$6 per treatment course, efforts are underway as of 2010 to bring the price down one dollar per course. It is commercially available in Africa and Asia. It has been used to treat more than 4.5 million people as of 2017.